Pharmaceuticals, Biotechnology & Life Sciences

ADVICENNE’s stock slump, negative P/E and 52‑week decline spotlight the firm’s struggle to innovate in pharma—can it reverse fortunes and tackle global health challenges?

Trulieve, a $2.2B healthcare cannabis firm, blends medical sales with growing political contributions—examining its market challenges and influence.

Discover why Iovance Biotherapeutics’ TIL‑based cancer immunotherapies could reshape oncology, and what its current negative P/E ratio means for investors.

Explore ImmunityBio’s battle: a biotech leader in cell & immunotherapy facing steep stock swings and a negative P/E, yet holding a $8.5 bn market cap that fuels investor hope for breakthrough cancer & disease treatments.

Vertex outperforms Regeneron with a three‑fold higher ROIC, showcasing superior capital discipline, efficient asset turnover, and a robust precision‑medicine pipeline for sustainable growth.

Thermo Fisher Scientific insider trades reveal CEO Marc N. Casper’s holdings and share activity, offering a clear view of leadership moves and stock trends.

GSK stock nears a 52‑week peak amid looming patent expirations; discover how its diverse pipeline may cushion margin pressure and drive future growth.

Cronos Group Inc. invites investors to its AGM on September 28, 2026, where audited financials, board elections, and cannabis‑industry strategy will be discussed.

FDA approves Gilead’s new HIV pill Bixlenvo, a single‑tablet combo that keeps patients suppressed and may boost the company’s market standing.

Discover how Bayer AG’s August 2026 highlights—Phase III REVEAL, Kerendia’s Japan approval, and the $7.25 bn Roundup settlement—shift its financial outlook and market prospects.